論文 - 岡田　佑輔

Risk of Thrombocytopenia by SSRIs or SNRIs in Patients With Depression Based on MID-NET: A Cohort Study in Japan.

Okada Y, Kajiyama K, Komamine M, Ando T, Hasegawa T, Ishiguro C, Nonaka T, Tsukuda M, Iwasaki Y, Ueda T, Horiuchi N, Iguchi T, Uyama Y

Clinical and translational science 18 （ 6 ） e70268 2025年06月

研究論文（学術雑誌）, 共著, 筆頭著者, 査読有り,  ISSN  1752-8054

• Access to Document (DOI)

New Function for Safety Signal Monitoring in MID-NET®: The Case of an Anti-COVID-19 Drug.

Okada Y, Ando T, Takahashi F, Watanabe K, Kajiyama K, Hasegawa T, Inomata S, Kinoshita Y, Watanabe S, Uyama Y

Clinical and translational science 18 （ 4 ） e70208 2025年04月

研究論文（学術雑誌）, 共著, 筆頭著者, 査読有り,  ISSN  1752-8054

• Access to Document (DOI)

Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET® in Japan.

Okada Y, Kajiyama K, Ishiguro C, Nonaka T, Komaki T, Kuga W, Komiyama N, Iguchi T, Horiuchi N, Uyama Y

The Journal of dermatological treatment 35 （ 1 ） 2373826 2024年12月

研究論文（学術雑誌）, 共著, 筆頭著者, 査読有り,  ISSN  0954-6634

• Access to Document (DOI)

Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses.

Okada Y, Inada K, Akazawa M

Journal of clinical psychopharmacology 44 （ 3 ） 263 - 271 2024年05月

研究論文（学術雑誌）, 共著, 筆頭著者, 査読有り,  ISSN  0271-0749

• Access to Document (DOI)

Prescription trend and lactic acidosis in patients prescribed metformin before and after the revision of package insert for allowing metformin administration to patients with …

T Waki, Y Okada, Y Kinoshita, K Kajiyama, C Ishiguro, Y Nakazato, ...

Frontiers in Medicine 10, 1294696 2024年

研究論文（学術雑誌）, 共著, 査読有り

Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan.

Okada Y, Inada K, Akazawa M

Schizophrenia research （Elsevier {BV}）  252   300 - 308 2023年02月

研究論文（学術雑誌）, 共著, 筆頭著者, 査読有り,  ISSN  0920-9964

• Access to Document (DOI)

Effects of medical service fee revision on reducing irrational psychotropic polypharmacy in Japan: an interrupted time-series analysis.

Okada Y, Akazawa M

Social psychiatry and psychiatric epidemiology （Springer Science and Business Media {LLC}）  57 （ 2 ） 411 - 422 2022年02月

研究論文（学術雑誌）, 共著, 筆頭著者, 査読有り,  ISSN  0933-7954

　概要を見る

<jats:title>Abstract</jats:title><jats:sec>
<jats:title>Purpose</jats:title>
<jats:p>According to the revised Japanese medical service fees aimed at reducing irrational psychotropic polypharmacy, medical service fees are reduced if the number of simultaneously prescribed psychotropic drugs exceeds the standard. This study primarily aims to examine the effect of the 2018 revision.</jats:p>
</jats:sec><jats:sec>
<jats:title>Methods</jats:title>
<jats:p>Using a large Japanese administrative claims database, we retrospectively identified five groups (April 2013–September 2018) prescribed at least one drug from the following drug groups: anxiolytics, hypnotics, sum of anxiolytics and hypnotics, antipsychotics, and antidepressants (study population in each group: 547,511, 406,524, 759,137, 112,929, and 201,046, respectively). We used an interrupted time-series design to evaluate changes in the proportion of patients prescribed more than the standard number of drugs.</jats:p>
</jats:sec><jats:sec>
<jats:title>Results</jats:title>
<jats:p>After the 2018 revision, the proportion of patients prescribed more than the standard number of drugs significantly decreased only for the sum of anxiolytics and hypnotics; estimated changes in level and trend were − 0.60% [− 0.69%, − 0.52%] and − 0.04% [− 0.06%, − 0.02%] per month, respectively. The proportion of patients exhibiting a decrease in the number of prescribed drugs from more than the standard to within the standard increased when the revision was enforced (April 2018); this proportion in April 2018 was 36.3%, while all other proportions were in the range of 12.1–22.3%.</jats:p>
</jats:sec><jats:sec>
<jats:title>Conclusion</jats:title>
<jats:p>The 2018 revision promoted a reduction in the number of prescribed drugs, which served as an important factor in the decrease in the proportion of patients prescribed more than the standard number of drugs for the sum of anxiolytics and hypnotics.</jats:p>
</jats:sec>

• Access to Document (DOI)

The requirements for additional strength biowaivers for immediate release solid oral dosage forms in international pharmaceutical regulators programme participating regulators …

C Crane, GML Santos, EAF Fernandes, C Simon, A Tam, DG Triana, ...

Journal of Pharmacy & Pharmaceutical Sciences 22, 486-500 2019年

研究論文（学術雑誌）, 共著, 査読有り

A survey of the regulatory requirements for the acceptance of foreign comparator products by participating regulators and organizations of the International Generic Drug …

AG Arieta, C Simon, GML Santos, IOC Lojero, ZR Martínez, C Rodrigues, ...

Journal of Pharmacy & Pharmaceutical Sciences 22, 28-36 2019年

研究論文（学術雑誌）, 共著, 査読有り

A survey of the regulatory requirements for BCS-based biowaivers for solid oral dosage forms by participating regulators and organisations of the international generic drug …

JE Van Oudtshoorn, A García-Arieta, GML Santos, C Crane, C Rodrigues, ...

Journal of Pharmacy & Pharmaceutical Sciences 21, 27-37 2018年

研究論文（学術雑誌）, 共著, 査読有り